Literature DB >> 19738253

Is the United States ready for QALYs?

Peter J Neumann1, Dan Greenberg.   

Abstract

Quality-adjusted life-years (QALYs) are used in cost-effectiveness analyses to aid coverage and reimbursement decisions worldwide. QALYs provide a flexible and convenient metric for measuring and comparing health outcomes across diverse diseases and treatments. But their use has stirred controversy about how accurately they reflect preferences for health care and whether their use is fair. We review the debate and the use of QALYs in other countries and discuss prospects for using them in the U.S. health care system. Strict adherence to a QALY approach is likely to prove unacceptable in the United States, but a more flexible use of QALYs could be beneficial.

Mesh:

Year:  2009        PMID: 19738253     DOI: 10.1377/hlthaff.28.5.1366

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  18 in total

Review 1.  International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Authors:  Adrian R Levy; Craig Mitton; Karissa M Johnston; Brian Harrigan; Andrew H Briggs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review.

Authors:  Aaron N Winn; Donatus U Ekwueme; Gery P Guy; Peter J Neumann
Journal:  Am J Prev Med       Date:  2015-10-23       Impact factor: 5.043

3.  Predicting health utilities for children with autism spectrum disorders.

Authors:  Nalin Payakachat; J Mick Tilford; Karen A Kuhlthau; N Job van Exel; Erica Kovacs; Jayne Bellando; Jeffrey M Pyne; Werner B F Brouwer
Journal:  Autism Res       Date:  2014-09-25       Impact factor: 5.216

4.  Cost-effectiveness studies of HPV self-sampling: A systematic review.

Authors:  Colin Malone; Ruanne V Barnabas; Diana S M Buist; Jasmin A Tiro; Rachel L Winer
Journal:  Prev Med       Date:  2020-01-03       Impact factor: 4.018

5.  Economics of public health programs for underserved populations: a review of economic analysis of the National Breast and Cervical Cancer Early Detection Program.

Authors:  Jaya S Khushalani; Justin G Trogdon; Donatus U Ekwueme; K Robin Yabroff
Journal:  Cancer Causes Control       Date:  2019-10-09       Impact factor: 2.506

6.  Stakeholder perspectives on a risk-benefit framework for genetic testing.

Authors:  Joshua A Roth; Louis P Garrison; Wylie Burke; Scott D Ramsey; Rick Carlson; David L Veenstra
Journal:  Public Health Genomics       Date:  2010-04-20       Impact factor: 2.000

7.  Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System.

Authors:  John S Wittenborn; Traci Clemons; Carl Regillo; Nadim Rayess; Danielle Liffmann Kruger; David Rein
Journal:  JAMA Ophthalmol       Date:  2017-05-01       Impact factor: 7.389

8.  US valuation of health outcomes measured using the PROMIS-29.

Authors:  Benjamin M Craig; Bryce B Reeve; Paul M Brown; David Cella; Ron D Hays; Joseph Lipscomb; A Simon Pickard; Dennis A Revicki
Journal:  Value Health       Date:  2014-12       Impact factor: 5.725

Review 9.  When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.

Authors:  Dan Greenberg; Craig Earle; Chi-Hui Fang; Adi Eldar-Lissai; Peter J Neumann
Journal:  J Natl Cancer Inst       Date:  2010-01-07       Impact factor: 13.506

Review 10.  Importance of cost-effectiveness and value in cancer care and healthcare policy.

Authors:  Ravinder Kang; Philip P Goodney; Sandra L Wong
Journal:  J Surg Oncol       Date:  2016-06-22       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.